N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea

Request For Quotation
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: Shaoguan Qicheng Biotechnology Co., Ltd  
Tel: 18122215013
Email: 780229652@qq.com
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Basic information
Product Name:N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea
Synonyms:N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea;3-bromo-N-[(2-methylphenyl)carbamothioyl]benzamide;Benzamide, 3-bromo-N-[[(2-methylphenyl)amino]thioxomethyl]-;TFCP2L1-IN-1
CAS:364621-46-5
MF:C15H13BrN2OS
MW:349.25
EINECS:
Product Categories:
Mol File:364621-46-5.mol
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Structure
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Chemical Properties
density 1.511±0.06 g/cm3(Predicted)
form Solid
pka8.67±0.70(Predicted)
color Off-white to light yellow
Safety Information
MSDS Information
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Usage And Synthesis
UsesTFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1’s active domain with anti-cancer activity. TFCP2L1-IN-1 synergizes with Sorafenib (HY-10201) to induce Apoptosis and reduces cell proliferation, invasion, metastasis, clonal formation and sphere-forming capacity in hepatocellular carcinoma cells[1].
References[1] Qiu D, et al. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. Oncogenesis. 2024 Sep 12;13(1):33. DOI:10.1038/s41389-024-00534-1
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Preparation Products And Raw materials
Tag:N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea(364621-46-5) Related Product Information
Doxorubicin hydrochloride Ruxolitinib 2-Deoxy-D-glucose MonoMethyl auristatin E ANGIOTENSIN II, HUMAN Carbonyl cyanide 3-chlorophenylhydrazone